

**Additional file 4** Change in VAS score while coughing from baseline to Week 8 (secondary endpoint) (mITT population)

	Mirogabalin add-on group (N = 63)		Conventional treatment group (N = 65)		Intergroup difference <sup>a</sup>
	Mean ± SD	Change from baseline	Mean ± SD	Change from baseline	
Baseline	68.3 ± 18.9		66.4 ± 18.8		
Day 1	62.7 ± 20.4	-5.6 ± 16.2 <i>P</i> = 0.008 <sup>b</sup>	54.9 ± 23.2	-11.4 ± 21.1 <i>P</i> < 0.001 <sup>b</sup>	<i>P</i> = 0.088
Week 2	32.0 ± 21.4	-36.6 ± 21.2 <i>P</i> < 0.001 <sup>b</sup>	33.0 ± 25.4	-33.2 ± 28.2 <i>P</i> < 0.001 <sup>b</sup>	<i>P</i> = 0.470
Week 4	15.6 ± 13.7	-53.0 ± 21.0 <i>P</i> < 0.001 <sup>b</sup>	20.5 ± 23.4	-44.8 ± 26.2 <i>P</i> < 0.001 <sup>b</sup>	<i>P</i> = 0.078
Week 8	8.5 ± 12.2	-59.2 ± 20.0 <i>P</i> < 0.001 <sup>b</sup>	13.1 ± 19.6	-51.9 ± 26.7 <i>P</i> < 0.001 <sup>b</sup>	<i>P</i> = 0.121

<sup>a</sup> vs. the conventional treatment group by *t*-test.

<sup>b</sup> vs. baseline by paired *t*-test.

mITT, modified intention-to-treat; SD, standard deviation; VAS, Visual Analogue Scale.